Literature DB >> 1446965

Sexual dysfunction and psychological distress in methadone maintenance.

W D Spring1, M L Willenbring, T L Maddux.   

Abstract

We administered the Derogatis Sexual Functioning Inventory to 25 methadone maintenance patients who had been on a stable dose of methadone for at least 2 months, and obtained ratings of depression and anxiety, levels of sex hormones, and liver function tests. Five subjects with significantly lower Global Sexual Satisfaction Index scores (p < .0001) had more psychological symptoms, higher methadone doses, poorer body image, and less sexual drive and satisfaction, but normal fund of sexual information and lifetime experience. Sexual dysfunction among methadone maintenance patients may be due to coexisting psychiatric problems rather than caused by opiates. Methadone patients presenting with sexual dysfunction should receive psychiatric evaluation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1446965     DOI: 10.3109/10826089209047354

Source DB:  PubMed          Journal:  Int J Addict        ISSN: 0020-773X


  11 in total

Review 1.  Methadone: applied pharmacology and use as adjunctive treatment in chronic pain.

Authors:  R Brown; C Kraus; M Fleming; S Reddy
Journal:  Postgrad Med J       Date:  2004-11       Impact factor: 2.401

Review 2.  Clinical factors associated with sexual dysfunction among men in methadone maintenance treatment and buprenorphine maintenance treatment: a meta-analysis study.

Authors:  A Yee; H S Loh; H M B Hisham Hashim; C G Ng
Journal:  Int J Impot Res       Date:  2014-07-03       Impact factor: 2.896

Review 3.  Sexual dysfunction in patients with alcohol and opioid dependence.

Authors:  Sandeep Grover; Surendra K Mattoo; Shreyas Pendharkar; Venkatesh Kandappan
Journal:  Indian J Psychol Med       Date:  2014-10

4.  The opiate dosage adequacy scale for identification of the right methadone dose--a prospective cohort study.

Authors:  Stephan Walcher; John Koc; Volker Reichel; Frank Schlote; Uwe Verthein; Jens Reimer
Journal:  BMC Pharmacol Toxicol       Date:  2016-04-07       Impact factor: 2.483

5.  The Evaluation of Relationship between Sexual Self-concept and Sexual Dysfunction in Individuals Undergoing Methadone Maintenance Treatment.

Authors:  Ghodratolah Rajabizadeh; Fatemeh Yazdanpanah; Mohammad Arash Ramezani
Journal:  Addict Health       Date:  2017-04

6.  Sexual behaviors among methadone maintenance patients in a mountainous area in northern Vietnam.

Authors:  Victoria L Boggiano; Huong Lan Thi Nguyen; Long Hoang Nguyen; Tho Dinh Tran; Hung Van Nguyen; Huong Thi Le; Hai Quan Le; Canh Dinh Hoang; Cuong Tat Nguyen; Bach Xuan Tran; Carl A Latkin; Nabil Zary; Thuc Minh Thi Vu
Journal:  Subst Abuse Treat Prev Policy       Date:  2017-08-25

7.  A comparison of sexual desire in opiate-dependent men receiving methadone and buprenorphine maintenance treatment.

Authors:  Anne Yee; Huai Seng Loh; Huai Heng Loh; Shahrzad Riahi; Chong Guan Ng; Ahmad Hatim Bin Sulaiman
Journal:  Ann Gen Psychiatry       Date:  2019-10-22       Impact factor: 3.455

8.  Magnesium Salt, a Simple Strategy to Improve Methadone Analgesia in Chronic Pain: An Isobolographic Preclinical Study in Neuropathic Mice.

Authors:  Valeria González; Teresa Pelissier; Victoria Cazanga; Alejandro Hernández; Luis Constandil
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

9.  Sexual dysfunction improved in heroin-dependent men after methadone maintenance treatment in Tianjin, China.

Authors:  Minying Zhang; Huifang Zhang; Cynthia X Shi; Jennifer M McGoogan; Baohua Zhang; Linglong Zhao; Mianzhi Zhang; Keming Rou; Zunyou Wu
Journal:  PLoS One       Date:  2014-02-10       Impact factor: 3.240

10.  When higher doses in opioid replacement treatment are still inadequate - association to multidimensional illness severity: a cohort study.

Authors:  Jens Reimer; Eduard Boniakowski; Christian Bachner; Bernd Weber; Wieland Tietje; Uwe Verthein; Stephan Walcher
Journal:  Subst Abuse Treat Prev Policy       Date:  2014-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.